Xintela develops treatment for aggressive breast cancer
Lund, Sweden, June 17, 2020 – Xintela has decided that the company’s next focus in it’s oncology programme will be triple-negative breast cancer, which is an aggressive form of breast cancer that often metastasizes and has a poor prognosis. This decision was made based on the accumulated positive preclinical results using proprietary function blocking antibodies […]
Xintela granted 1 million SEK from Vinnova
Lund, Sweden, May 8, 2020 – Xintela has been granted 1 million SEK from Vinnova in the call for “ Innovations in the wake of the crisis – Restructuring of society, operations and production in the wake of the corona epidemic.”. The grant concerns the funding of a preclinical study to evaluate Xintela’s stem cells […]
Xintela granted 2 million SEK from Vinnova
Lund, Sweden, March 27, 2020 – Xintela has been granted 2 million SEK from Vinnova in the call for “Innovation projects in small and medium-sized companies”. The grant concerns one of the company’s cancer projects and the work to develop targeted therapies for aggressive cancers with integrin 10-binding ADCs. “This is very good news for […]
Xintela publishes positive preclinical results from equine study
Lund, Sweden, 3 February, 2020 – Xintela announces that the results from the company’s stem cell study on horses has now been published in the respected scientific journal The American Journal of Sports Medicine. The publication demonstrates that the stem cell treatment is safe and that it has a significantly positive effect on both cartilage […]
Positive preclinical results in Xintela’s glioblastoma project
Lund, Sweden, December 11, 2019 – Xintela AB (publ) announces positive preclinical results in the glioblastoma project. Xintela has developed function-blocking antibodies that bind to the company’s target integrin a10b1 and identified an antibody that suppresses the growth of glioblastoma tumors in a preclinical model. In order to develop targeted antibody-based therapy for the aggressive […]
Xintela publishes interim report for the third quarter
Summary of the interim report The “company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. First nine months of the year (1 Jan 2019-30 Sep 2019)· Income amounted to TSEK 3 (1,012).· Loss before tax totalled TSEK -28,081 (-17,581).· Loss per share* was SEK -0.71 (-0.58).· At 30 September 2019, the equity/assets […]
Xintela publishes results from glioblastoma study
Lund, Sweden, 26 April 2019 – Xintela announces that the results of the company’s glioblastoma study have now been published in the renowned international scientific journal Cancers. The publication demonstrates and discusses that Xintela’s marker, integrin a10b1, regulates important functions of glioblastoma cells and is a potential new therapeutic target for the treatment of the […]
Xintela appoints Sven Kili as Chief Operating Officer
Lund, Sweden, 16 April 2019 – Sven Kili, an Executive Director and the Chief Medical Officer of Xintela, extends his commitment by taking on the Chief Operating Officer (COO) role. Sven Kili is a surgeon and specialist in orthopedics and, through leading positions in pharmaceutical companies including Genzyme, Sanofi, and GSK, has many years’ experience […]
Year-end Report 2018
The aim is set for clinical studies The final quarter of the year was very eventful, and successful in terms of both projects and financing. We conducted a directed share issue of MSEK 50 to the German orthopaedic company Bauerfeind AG. In the companies stem-cell project, our aim is to commence clinical trials in Australia. […]
